| |
Type 2 DM patients n = 309
|
Non-DM subjects n = 505
|
P value
|
|---|
|
Age (years)
|
65.4 ± 10.4
|
64.8 ± 10.8
|
0.57
|
|
Gender (Women/men)
|
74/235
|
123/382
|
0.90
|
|
BMI (Kg/m2)
|
27.2 ± 3.9
|
25.6 ± 3.4
|
< 0.001
|
|
Hypertension (%)
|
252 (81.0)
|
348 (68.9)
|
< 0.001
|
|
Smoking (%)
|
64 (20.7)
|
106 (21.0)
|
0.93
|
|
Hypercholesterolemia (%)
|
139 (45.1)
|
228 (45.1)
|
1.00
|
|
Cholesterol (mg/dl)
| | | |
|
Total
|
164.7 ± 33.4
|
175.1 ± 37.3
|
< 0.001
|
|
HDL-Cholesterol
|
40.1 ± 11.1
|
44.9 ± 12.7
|
< 0.001
|
|
LDL-Cholesterol
|
99.6 ± 28.4
|
110.0 ± 33.6
|
< 0.001
|
|
Triglyceride (mg/dl)
|
155.0 ± 96.8
|
138.0 ± 85.4
|
< 0.001
|
|
Creatinine (mg/dl)
|
1.3 ± 1.0
|
1.1 ± 0.5
|
< 0.001
|
|
eGFR (ml/min per 1.73 m2)
|
70.8 ± 30.0
|
80.1 ± 24.9
|
< 0.001
|
|
Fasting blood sugar(mg/dl)
|
138.0 ± 48.3
|
92.7 ± 14.5
|
< 0.001
|
|
ADMA (μmol/l)
|
0.46 ± 0.09
|
0.45 ± 0.10
|
0.12
|
|
L-arginine (μmol/l)
|
88.3 ± 29.7
|
97.3 ± 33.3
|
< 0.001
|
|
L-arginine/ADMA
|
196.0 ± 67.0
|
225.0 ± 86.1
|
< 0.001
|
|
Medications
| | | |
|
Anti-platelet drug
|
272 (88.0)
|
420 (83.2)
|
0.07
|
|
Statins
|
144 (46.4)
|
201 (39.8)
|
0.06
|
|
ACE-Inhibitor/ARB
|
108 (35.0)
|
111 (22.0)
|
<0.001
|
|
Calcium channel blocker
|
69 (22.3)
|
115(22.8)
|
0.88
|
|
Hypoglycemic treatments
| | | |
|
Insulin (%)
|
49 (15.8)
|
-
|
-
|
|
OHA (%)
|
244 (79.0)
|
-
|
-
|
|
Insulin + OHA (%)
|
8 (2.6)
|
-
|
-
|
- ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker. BMI: body mass index; eGFR: estimated glomerular filtration rate; OHA: oral hypoglycemic agents.
